Literature DB >> 16869757

Genomic progression in mouse models for liver tumors.

A D Tward1, K D Jones, S Yant, M A Kay, R Wang, J M Bishop.   

Abstract

The principal cause of human liver cancer is infection with hepatitis viruses B and C, but tumor progression is fueled by ensuing perturbations that confer gain of function on proto-oncogenes or loss of function on tumor suppressor genes. Frequent among these perturbations is overexpression of the proto-oncogene MET. We have modeled the pathogenesis of liver tumors by expressing conditional transgenes of MET in the hepatocytes of inbred mice. The response to the MET transgene varied with both the magnitude and timing of its expression but included hyperplasia of hepatic progenitor cells, as well as benign and malignant tumors that display both phenotypic and genotypic resemblances to human counterparts. The results reveal MET to be a crucial switch in the development of the liver; dramatize how different cellular compartments within a developmental lineage can give rise to distinctive tumor stem cells; delineate rules of tumor progression; provide evidence that the experimental tumors in mice are authentic models for human tumors; and support a role for MET in the genesis of human liver tumors. The models should be useful in elucidating the mechanisms of tumorigenesis and in the preclinical testing of new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869757     DOI: 10.1101/sqb.2005.70.058

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  8 in total

Review 1.  Cancer gene discovery in hepatocellular carcinoma.

Authors:  Lars Zender; Augusto Villanueva; Victoria Tovar; Daniela Sia; Derek Y Chiang; Josep M Llovet
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

2.  MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.

Authors:  Brittany Anderton; Roman Camarda; Sanjeev Balakrishnan; Asha Balakrishnan; Rebecca A Kohnz; Lionel Lim; Kimberley J Evason; Olga Momcilovic; Klaus Kruttwig; Qiang Huang; Guowang Xu; Daniel K Nomura; Andrei Goga
Journal:  EMBO Rep       Date:  2017-02-20       Impact factor: 8.807

3.  Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells.

Authors:  Edward Kai-Hua Chow; Ling-ling Fan; Xin Chen; J Michael Bishop
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

4.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

5.  Transcription-dependent spatial arrangements of CFTR and conserved adjacent loci are not conserved in human and murine nuclei.

Authors:  Nicolas Sadoni; Bianca-Sabrina Targosz; Andreas Englmann; Stephanie Fesser; Jeannette Koch; Dirk Schindelhauer; Daniele Zink
Journal:  Chromosoma       Date:  2008-04-12       Impact factor: 4.316

6.  Monocytes promote liver carcinogenesis in an oncogene-specific manner.

Authors:  Vladislava Juric; Brian Ruffell; Kimberley J Evason; Junjie Hu; Li Che; Linlin Wang; Xin Chen; J Michael Bishop
Journal:  J Hepatol       Date:  2015-11-27       Impact factor: 25.083

7.  A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.

Authors:  Daniel Dauch; Ramona Rudalska; Giacomo Cossa; Jean-Charles Nault; Tae-Won Kang; Torsten Wuestefeld; Anja Hohmeyer; Sandrine Imbeaud; Tetyana Yevsa; Lisa Hoenicke; Tatu Pantsar; Przemyslaw Bozko; Nisar P Malek; Thomas Longerich; Stefan Laufer; Antti Poso; Jessica Zucman-Rossi; Martin Eilers; Lars Zender
Journal:  Nat Med       Date:  2016-05-23       Impact factor: 53.440

Review 8.  In vivo Reprogramming of Cancer Metabolism by MYC.

Authors:  Roman Camarda; Jeremy Williams; Andrei Goga
Journal:  Front Cell Dev Biol       Date:  2017-04-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.